HONG KONG — JUNE 30, 2025 — Edwin Kwok & Co (“EKC”) is pleased to announce that recently it acted as Hong Kong legal adviser to RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) in its exclusive license agreement with Vor Biopharma Inc. (NASDAQ: VOR), a NASDAQ-listed biotech company. This agreement has granted Vor Bio exclusive global rights (excluding Greater China) to develop, manufacture and commercialize RemeGen’s self-developed Telitacicept, a first-in-class dual-target fusion protein that inhibits B-cell differentiation to treat autoimmune diseases.
Pursuant to the agreement, Remegen will receive an initial payment of US$125 million, consisting of an upfront cash payment of US$45 million and warrants valued at US$80 million to subscribe for 320 million shares of Vor Bio’s common stock (or 23% of Vor Bio’s enlarged share capital), as well as potential milestone payments of up to US$4.105 billion.
RemeGen Co., Ltd. is a biopharmaceutical company in China dedicated to discovering, developing, and commercializing innovative biologic drugs for autoimmune, oncology and ophthalmic diseases.
In addition, EKC acted as Hong Kong legal adviser to Brii Biosciences Limited (HKEX: 2137) in its exclusive license with Joincare Pharmaceutical Group Industry Co., Ltd (“Joincare”). Pursuant to the agreement, Joincare will obtain an exclusive license from Brii for the research, development, and commercialization of BRII-693, a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug-and extensively drug-resistant gram-negative bacterial infections, in Greater China. In return, Brii has received an upfront payment and will receive additional development and commercial milestone payments and tiered royalties based on net product sales.
Brii Biosciences Limited is a biotechnology company dedicated to developing innovative therapies in areas of high unmet medical needs, particularly infectious diseases.
Our team was led by Founder and Managing Partner, Edwin Kwok, and includes our consultants Lillian Cheung and Yuki Tsang, advising on Hong Kong regulatory compliance.
EKC focuses on a full range of corporate, capital markets, mergers and acquisitions, private equity, and regulatory matters. With combined U.S., Hong Kong, and English law capabilities, we provide integrated, comprehensive, and innovative solutions on a wide variety of matters globally.
